带状疱疹眼病角膜并发症行穿透性角膜移植的长期结局
回顾性分析53眼因带状疱疹眼病角膜并发症行穿透性角膜移植的病例,随访4.0±3.8年。术后无带状疱疹角膜炎复发,1、2-4、≥5年植片透明率分别为94%、82%、70%,视力在1年时改善但未持续,长期口服阿昔洛韦对视力或植片存活无显著益处。
要点
- HZO角膜并发症行PKP后无带状疱疹角膜炎复发,植片长期透明率较好。
- 术后常见并发症为眼表愈合困难(22.6%)和青光眼(26.4%)。
- 长期预防性口服阿昔洛韦未改善视力(p=0.2132)或植片存活(p=0.241)。
核心结论
- 即使术前存在显著危险因素,HZO角膜并发症行PKP仍可获得良好的结构和视力结果。
- 多数植片保持透明,但长期视力潜力可能受共病眼病限制。
- 术后预防性口服阿昔洛韦未改善结局。
研究设计与样本
- 回顾性病历复习,纳入Kellogg Eye Center因HZO角膜并发症行PKP的53眼(53例患者)。
- PKP时平均年龄68.0±16.4岁,随访4.0±3.8年,从活动性HZO到PKP的静息期6.5±5.3年。
主要发现
- 术前25眼(47.2%)完全无感觉,16眼(30.2%)四个象限均有深部角膜新生血管。
- 25眼(47.2%)存在共病眼病,包括白内障、青光眼和黄斑病。
- 最常见并发症为眼表愈合困难(12/53,22.6%)和青光眼(14/53,26.4%)。
- 30%的眼需要一次或多次额外术后操作,最常见为睑缘缝合(10/53,18.9%)和羊膜移植(6/53,11.3%)。
关键数值与推荐
- 术后1年、2-4年、≥5年植片透明率分别为94%、82%、70%。
- 术后1年视力改善(p<0.0001),但改善未持续。
- 长期阿昔洛韦对视力无显著益处(p=0.2132),对植片存活无显著益处(p=0.241)。
临床怎么用
- 对HZO角膜并发症患者,PKP可作为重建结构和改善视力的选择,即使术前风险较高。
- 术后需关注眼表愈合困难和青光眼,必要时行睑缘缝合或羊膜移植。
- 长期预防性口服阿昔洛韦未显示改善视力或植片存活,决策需个体化。
局限性
- 回顾性单中心病历复习,样本量53眼。
- 长期视力潜力可能受共病眼病限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIM: To review the long-term outcomes of penetrating keratoplasty (PKP) for corneal complications of herpes zoster ophthalmicus (HZO). METHODS: We reviewed the medical records of 53 eyes of 53 patients who underwent PKP due to corneal complications of HZO at the Kellogg Eye Center. RESULTS: The mean age of patients at the time of PKP was 68.0±16.4 years, with a follow-up of 4.0±3.8 years and quiescent period of 6.5±5.3 years from active HZO to PKP. Preoperatively, 25 (47.2%) eyes were completely anaesthetic, while 16 (30.2%) had deep corneal neovascularisation in four quadrants. Comorbid ocular disease, including cataract, glaucoma and macular disease, was present in 25 (47.2%) eyes. Twenty patients (37.8%) received acyclovir for the entire postoperative period. There were no recurrences of zoster keratitis in any eye. The most common complications were difficulty healing the ocular surface (12/53, 22.6%) and glaucoma (14/53, 26.4%). Thirty per cent of the eyes required one or more additional postoperative procedures, most commonly tarsorrhaphy (10/53, 18.9%) and amniotic membrane graft (6/53, 11.3%). At 1, 2-4 and ≥5 years, 94%, 82% and 70% grafts remained clear, respectively. Visual acuity improved at 1 year postoperatively (p<0.0001), but this improvement was not sustained. There was no significant benefit of long-term acyclovir on visual acuity (p=0.2132) or graft survival (p=0.241). CONCLUSIONS: Even in eyes with significant preoperative risk factors, PKP for the corneal complications of HZO can achieve favourable tectonic and visual results. Although most grafts remained clear, long-term visual potential may be limited by comorbid ocular diseases. Prophylactic postoperative oral acyclovir did not improve outcomes.
引用
- Tanaka TS, Hood CT, Kriegel MF, et al. Long-term outcomes of penetrating keratoplasty for corneal complications of herpes zoster ophthalmicus. Br J Ophthalmol. 2019. PMID: 30733209. doi:10.1136/bjophthalmol-2018-313602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。